1. Staffs and Students (April, 2012)

Professor
Nobuyuki MIYASAKA
Masayoshi HARIGAI(1)

Associate Professor
Hitoshi KOHSUKA
Tetsuo KUBOTA(2), Ryuji KOIKE(3), Kazuki TAKADA(4), Toshihiro NANKI(1),

Junior Associate Professor
Hideyuki IWAI

Assistant Professor
Fumitaka MIZOGUCHI, Akito TAKAMURA, Kaori WATANABE(1), Ryoko SAKAI(1)

Visiting Lecturer
Rieko TSUBATA, Hiroyuki HAGIYAMA, Yoshiki NONOMURA, Yukiko KOMANO, Kenji NAGASAKA, Jun OGAWA, Fumihito SUZUKI, Kayoko KANEKO, Peter Y. Shane, Toru KINO

Graduate Student

Research Student
Chie MIYABE

Resident Physician
Mineto OTA, Hiroyoshi MORI, Yoji KOMIYA, Mari NAKAJIMA

Research Worker
Yusuke TAGATA

Office Administrator
Rie FUJIME, Kaori KONNO, Tomoko TAKAHASHI(1), Momoko MITSUISHI, Marie YAJIMA(1)

Technical Staff
Eri YOSHIMOTO, Sayaka ONO

(*GCOE QAISS)

(1) Department of Pharmacovigilance, (2) Health care sciences, (3) Clinical Research Center, (4) Clinical Clerkship Working Group

2. Purpose of Education
We have provided medical students and graduates with the opportunity to obtain the ability to identify important clinical problems and to solve them by clinical reasoning through their active participation into the diagnosis and management of various rheumatic diseases.

3. Research Subjects
Following studies have been extensively carried out in our laboratory with various biochemical, immunological, molecular biological and statistical techniques:

1) Development of new therapeutics for the treatment of rheumatoid arthritis targeting cell cycle regulators, inflammatory molecules and synovial fibroblasts.
2) Investigation of mechanism and development of new therapeutics for the treatment of polymyositis.
3) Analysis of the roles of chemokine and bioactive lipid on the pathogenesis of rheumatic diseases.
4) Establishment of evidence-based treatment of rheumatic diseases by implementing several cohort studies.

4. Clinical Services
We have provided care to a large number of patients with diverse rheumatic diseases with 27,957 clinic visits and 274 hospital admissions in 2012. We have aimed to practice evidence-based medicine and to provide care that is in accordance...
with the global standard. We have contributed to the development of potential new drugs and treatments through participation into industry- as well as investigator-initiated clinical trials for chemical and biological agents. We have also contributed to the refinement of the care of rheumatoid arthritis patients through the conduct of various pharmacovigilance studies.

5. Publications

Original Article


23. Umezawa N, Kohsaka H, Nanki T, Watanabe K, Tanaka M, Shane PY, Miyasaka N. Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG. Mod Rheumatol 2012.


